Joel Macy, MD
Family Medicine · Fairborn, OHNPI 1225031099
Payments from drug & device makers
Across 420 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Pfizer$510
- Novo Nordisk$461
- Lilly USA, LLC$458
- Amgen$297
- plus $3K from 33 others
What the payments were for
- Food & beverage$6,981100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $1,614 |
| AstraZeneca | 52 | $1,009 |
| Pfizer | 32 | $510 |
| Novo Nordisk | 30 | $461 |
| Lilly USA, LLC | 30 | $458 |
| Amgen | 18 | $297 |
| Astellas Pharma US Inc | 10 | $203 |
| GSK | 13 | $203 |
| Bayer | 9 | $190 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $166 |
| Antares Pharma, Inc. | 8 | $160 |
| Abbott | 9 | $156 |
| Axsome Therapeutics, Inc. | 7 | $129 |
| Exact Sciences | 6 | $111 |
| Halozyme Inc | 5 | $111 |
| Idorsia Pharmaceuticals US Inc | 7 | $107 |
| Corcept Therapeutics | 5 | $102 |
| Boehringer Ingelheim | 5 | $99 |
| Kowa Pharmaceuticals America, Inc. | 6 | $94 |
| Esperion Therapeutics, Inc. | 5 | $86 |
| Merck | 4 | $81 |
| Phathom Pharmaceuticals, Inc. | 4 | $78 |
| Johnson & Johnson | 4 | $77 |
| Amneal Pharmaceuticals LLC | 3 | $61 |
| Medtronic | 3 | $57 |
| Novartis | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Organogenesis Inc. | 1 | $40 |
| Shield Therapeutics Inc | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Dexcom, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $17 |
| Radius Health, Inc. | 1 | $14 |
| Neos Therapeutics, LP | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$6,995 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $81,209 |
| JardianceEmpagliflozin | 47 | $70,677 |
| JanuviaSitagliptin Phosphate | 68 | $61,201 |
| MounjaroTirzepatide | 37 | $54,126 |
| XareltoRivaroxaban | 29 | $39,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $29,736 |
| TrulicityDulaglutide | 18 | $28,453 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $16,575 |
| OzempicSemaglutide | 11 | $15,637 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $14,534 |
| Atorvastatin Calcium | 497 | $6,627 |
| Hydroxyzine Hcl | 101 | $5,341 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $5,137 |
| Colesevelam Hcl | 12 | $4,901 |
| Lansoprazole | 32 | $4,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $458 | $82,57855 claims |
| PfizerEliquis | $510 | $81,20965 claims |
| MerckJanuvia, Janumet Xr | $81 | $77,77682 claims |
| Boehringer IngelheimJardiance | $99 | $70,67747 claims |
| Johnson & JohnsonXarelto | $77 | $39,40229 claims |
| GSKTrelegy Ellipta | $203 | $29,73633 claims |
| Novo NordiskOzempic | $461 | $15,63711 claims |
| AbbVieSynthroid | $1,614 | $3,67359 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $61 | $2,580310 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Fairborn
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.